Nashville, Tennessee 37232


Purpose:

The investigators plan to conduct a randomized trial comparing the intubation success rate and time of the King Vision Video Laryngoscope to the Glidescope video laryngoscope in order to demonstrate the comparability of the devices.


Study summary:

Both the King Vision and Glidescope video laryngoscopes are advanced airway devices that are relatively low cost and are designed to improve the efficiency of both routine and difficult intubation. Both systems use disposable blades, which eliminates the need for blade sterilization and may minimize the risk of infectious exposure to patients and improve cost and efficiency associated with the sterilization processing of non-disposable laryngoscopes. The Glidescope has been commercially available longer than the King Vision, and has been more frequently studied. Although similar in many respects, the King Vision and Glidescope systems have differing designs which may result in differences in speed and success in the management of routine and/or difficult airways.


Criteria:

Inclusion Criteria: - Adult patients scheduled for elective, ambulatory surgery requiring general anesthesia and endotracheal intubation Exclusion Criteria: - Patients who require rapid sequence induction and intubation or fiberoptic intubation. - Pregnancy


NCT ID:

NCT02324465


Primary Contact:

Principal Investigator
Douglas Hester, MD
Vanderbilt University Medical Center

Douglas Hester, MD
Phone: 615-343-9419
Email: doug.hester@Vanderbilt.Edu


Backup Contact:

N/A


Location Contact:

Nashville, Tennessee 37232
United States

Douglas Hester, MD
Phone: 615-343-9419
Email: doug.hester@Vanderbilt.Edu

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: March 16, 2018

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

If you would like to be contacted by the clinical trial representative please fill out the form below.